PE20240765A1 - Compuestos para la inhibicion de nlrp3 y usos de estos - Google Patents

Compuestos para la inhibicion de nlrp3 y usos de estos

Info

Publication number
PE20240765A1
PE20240765A1 PE2023002788A PE2023002788A PE20240765A1 PE 20240765 A1 PE20240765 A1 PE 20240765A1 PE 2023002788 A PE2023002788 A PE 2023002788A PE 2023002788 A PE2023002788 A PE 2023002788A PE 20240765 A1 PE20240765 A1 PE 20240765A1
Authority
PE
Peru
Prior art keywords
nlrp3
alkyl
compounds
cycloalkyl
halo
Prior art date
Application number
PE2023002788A
Other languages
English (en)
Inventor
Stephane Dorich
Jason Burch
Miguel St-Onge
Amandine Chefson
Alexandre Côte
Ramsay Beveridge
Stephane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of PE20240765A1 publication Critical patent/PE20240765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion esta relacionada con inhibidores de NLRP3 utiles en el tratamiento de enfermedades y trastornos asociados con la modulacion de las proteinas NLRP3. En particular, la presente invencion se refiere a un compuesto con la Formula (I) o una sal, un solvato, un clatrato, entre otros; donde: X es N(Ra), O, S o C(Rb)(Rc); Ra es H, alquilo C1-C6, haloalquilo C1-C6, entre otros; o Ra se cicla con R1 para formar un heterocicloalquilo de 3 a 8 miembros; Rb es H o alquilo C1-C6; Rc es H o alquilo C1-C6; o Rb y Rc, junto con los atomos a los que estan unidos, forman un cicloalquilo C3-C8; Y es cicloalquilo C3-C8, heterocicloalquilo de 3 a 8 miembros, arilo C6-C10, entre otros; R1 es alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, entre otros; R2 es H, halo, ciano, entre otros; R3 es H, halo, ciano, entre otros; o R2 y R3, junto con los atomos a los que estan unidos, forman un cicloalquilo C3-C8, heterocicloalquilo de 3 a 8 miembros, arilo C6-C10 o heteroarilo de 5 a 9 miembros, donde el cicloalquilo C3-C8, heterocicloalquilo de 3 a 8 miembros, arilo C6-C10 o heteroarilo de 5 a 9 miembros esta opcionalmente sustituido con uno o mas R2a; R2a es hidrogeno, deuterio, alquilo C1-C6, halo o haloalquilo C1-C6. Ademas, se refiere a compuestos y composiciones farmaceuticas que inhiben NLRP3, metodos para el tratamiento de enfermedades y trastornos asociados con NLRP3 mediante el uso de dichos compuestos y composiciones farmaceuticas, y metodos para sintetizar dichos compuestos y composiciones.
PE2023002788A 2021-04-07 2022-04-07 Compuestos para la inhibicion de nlrp3 y usos de estos PE20240765A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof
PCT/US2022/023893 WO2022216971A1 (en) 2021-04-07 2022-04-07 Pyridazine compounds for inhibiting nlrp3

Publications (1)

Publication Number Publication Date
PE20240765A1 true PE20240765A1 (es) 2024-04-17

Family

ID=81385286

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002788A PE20240765A1 (es) 2021-04-07 2022-04-07 Compuestos para la inhibicion de nlrp3 y usos de estos

Country Status (14)

Country Link
US (5) US11319319B1 (es)
EP (2) EP4331668A3 (es)
JP (2) JP2024514837A (es)
KR (1) KR20230167394A (es)
CN (2) CN117510495A (es)
AU (2) AU2022256052A1 (es)
BR (1) BR112023020483A2 (es)
CA (1) CA3214676A1 (es)
CL (1) CL2023002973A1 (es)
CO (1) CO2023013356A2 (es)
IL (2) IL308378A (es)
PE (1) PE20240765A1 (es)
TW (2) TW202330522A (es)
WO (1) WO2022216971A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022253326A1 (zh) * 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
AU2022304254A1 (en) 2021-07-02 2024-02-08 Astrazeneca Ab Nlrp3 inflammasome inhibitors
CA3226995A1 (en) 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
CA3229539A1 (en) * 2021-08-25 2023-03-02 Xiaoyan Zhang Inhibitors of nlrp3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) * 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202345836A (zh) * 2022-03-25 2023-12-01 美商凡特斯治療美國公司 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
WO2023186020A1 (en) * 2022-03-31 2023-10-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2024013395A1 (en) * 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
WO2024064245A1 (en) 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) * 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
WO2024097629A1 (en) * 2022-10-31 2024-05-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
WO2024094185A1 (zh) * 2022-11-04 2024-05-10 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303061A (es) * 1969-05-03 1973-01-17
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
ES2224130T3 (es) * 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP1745039A4 (en) * 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
KR102507847B1 (ko) * 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof

Also Published As

Publication number Publication date
TW202330522A (zh) 2023-08-01
WO2022216971A1 (en) 2022-10-13
AU2023263450A1 (en) 2023-11-23
BR112023020483A2 (pt) 2023-11-21
US11319319B1 (en) 2022-05-03
TW202304905A (zh) 2023-02-01
JP2024050527A (ja) 2024-04-10
WO2022216971A9 (en) 2022-12-08
IL308378A (en) 2024-01-01
US20240174668A1 (en) 2024-05-30
JP2024514837A (ja) 2024-04-03
CA3214676A1 (en) 2022-10-13
IL307303A (en) 2023-11-01
EP4320102A1 (en) 2024-02-14
US20230159526A1 (en) 2023-05-25
EP4331668A2 (en) 2024-03-06
AU2022256052A1 (en) 2023-11-16
US20240158396A1 (en) 2024-05-16
KR20230167394A (ko) 2023-12-08
CO2023013356A2 (es) 2023-10-30
CL2023002973A1 (es) 2024-03-08
CN117510495A (zh) 2024-02-06
EP4331668A3 (en) 2024-06-05
CN117500792A (zh) 2024-02-02
US20220340567A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
PE20240765A1 (es) Compuestos para la inhibicion de nlrp3 y usos de estos
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
PE20211203A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PA8517101A1 (es) Derivados de tropano ùtiles en terapia
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
ECSP066459A (es) Miméticos de glucocorticoides, métodos de preparación, composiciones farmacéuticas y usos de los mismos
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
ECSP066958A (es) Compuestos de morfolina
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
AR066972A1 (es) Derivados azapeptidicos
PE20200445A1 (es) Inhibidores pirazolicos de magl
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
PE20211781A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina